{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:44:30Z","timestamp":1790847870963,"version":"4.1.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41386-025-02107-1","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T18:44:29Z","timestamp":1745347469000},"page":"1210-1223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronic, combinatorial targeting of NMDARs and 5-HT4Rs exerts extended behavioral effects against stress-induced perseverative behavior and hyponeophagia"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-1389","authenticated-orcid":false,"given":"Briana K.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Whye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise C.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Moniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Mendez-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain M.","family":"Gardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0506-6688","authenticated-orcid":false,"given":"Denis J.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Weisblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-2020","authenticated-orcid":false,"given":"Christine A.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"2107_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.psc.2023.02.012","volume":"46","author":"C Vas","year":"2023","unstructured":"Vas C, Jain A, Trivedi M, Jha MK, Mathew SJ. Pharmacotherapy for treatment-resistant depression: antidepressants and atypical antipsychotics. Psychiatr Clin North Am. 2023;46:261\u201375.","journal-title":"Psychiatr Clin North Am"},{"key":"2107_CR2","first-page":"116","volume":"13","author":"VL Ruberto","year":"2020","unstructured":"Ruberto VL, Jha MK, Murrough JW. Pharmacological treatments for patients with treatment-resistant depression. Pharm Basel Switz. 2020;13:116.","journal-title":"Pharm Basel Switz"},{"key":"2107_CR3","first-page":"PCC.12m01364","volume":"14","author":"T-S Lee","year":"2012","unstructured":"Lee T-S, Nkouibert Assam P, Gersing KR, Chan E, Burchett BM, Sim K, et al. The effectiveness of antidepressant monotherapy in a naturalistic outpatient setting. Prim Care Companion CNS Disord. 2012;14:PCC.12m01364.","journal-title":"Prim Care Companion CNS Disord"},{"key":"2107_CR4","first-page":"156","volume":"14","author":"BW Dunlop","year":"2016","unstructured":"Dunlop BW. Evidence-based applications of combination psychotherapy and pharmacotherapy for depression. Focus Am Psychiatr Publ. 2016;14:156\u201373.","journal-title":"Focus Am Psychiatr Publ"},{"key":"2107_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881115581093","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol Oxf Engl. 2015;29:459\u2013525.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"2107_CR6","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jad.2009.06.042","volume":"117","author":"SV Parikh","year":"2009","unstructured":"Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord. 2009;117:S15\u201325.","journal-title":"J Affect Disord"},{"key":"2107_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3109\/15622975.2014.1001786","volume":"16","author":"M Bauer","year":"2015","unstructured":"Bauer M, Severus E, K\u00f6hler S, Whybrow PC, Angst J, M\u00f6ller H-J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16:76\u201395.","journal-title":"World J Biol Psychiatry"},{"key":"2107_CR8","first-page":"16","volume":"4","author":"M Fava","year":"2007","unstructured":"Fava M, Targum SD. Augmentation and combination strategies to treat the residual symptoms of major depressive disorder. Psychiatry Edgmont Pa Townsh. 2007;4:16\u201318.","journal-title":"Psychiatry Edgmont Pa Townsh"},{"key":"2107_CR9","first-page":"301","volume":"1","author":"C Moret","year":"2005","unstructured":"Moret C. Combination\/augmentation strategies for improving the treatment of depression. Neuropsychiatr Dis Treat. 2005;1:301\u20139.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2107_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"2107_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nm.4050","volume":"22","author":"RS Duman","year":"2016","unstructured":"Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238\u201349.","journal-title":"Nat Med"},{"key":"2107_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ynstr.2018.09.001","volume":"9","author":"CE Strong","year":"2018","unstructured":"Strong CE, Kabbaj M. On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods. Neurobiol Stress. 2018;9:166\u201375.","journal-title":"Neurobiol Stress"},{"key":"2107_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","volume":"72","author":"J Kryst","year":"2020","unstructured":"Kryst J, Kawalec P, Mitoraj AM, Pilc A, Laso\u0144 W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep PR. 2020;72:543\u201362.","journal-title":"Pharmacol Rep PR"},{"key":"2107_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","volume":"348","author":"G d\u2019Andrea","year":"2024","unstructured":"d\u2019Andrea G, Pettorruso M, Di Lorenzo G, Rhee TG, Chiappini S, Carullo R, et al. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data. J Affect Disord. 2024;348:314\u201322.","journal-title":"J Affect Disord"},{"key":"2107_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76:893\u2013903.","journal-title":"JAMA Psychiatry"},{"key":"2107_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428\u201338.","journal-title":"Am J Psychiatry"},{"key":"2107_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.psc.2023.02.003","volume":"46","author":"A Feeney","year":"2023","unstructured":"Feeney A, Papakostas GI. Pharmacotherapy: ketamine and esketamine. Psychiatr Clin North Am. 2023;46:277\u201390.","journal-title":"Psychiatr Clin North Am"},{"key":"2107_CR18","doi-asserted-by":"publisher","unstructured":"Jiang Y, Du Z, Shen Y, Zhou Q, Zhu H. The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. Eur Arch Psychiatry Clin Neurosci. 2023. https:\/\/doi.org\/10.1007\/s00406-023-01732-5.","DOI":"10.1007\/s00406-023-01732-5"},{"key":"2107_CR19","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s12325-021-01732-8","volume":"38","author":"EP McMullen","year":"2021","unstructured":"McMullen EP, Lee Y, Lipsitz O, Lui LMW, Vinberg M, Ho R, et al. Strategies to prolong ketamine\u2019s efficacy in adults with treatment-resistant depression. Adv Ther. 2021;38:2795\u2013820.","journal-title":"Adv Ther"},{"key":"2107_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","volume":"182","author":"KN Fountoulakis","year":"2025","unstructured":"Fountoulakis KN, Saitis A, Schatzberg AF. Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis. Am J Psychiatry. 2025;182:259\u201375.","journal-title":"Am J Psychiatry"},{"key":"2107_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/1568007043482615","volume":"3","author":"J Bockaert","year":"2004","unstructured":"Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3:39\u201351.","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"2107_CR22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/j.1471-4159.2009.06050.x","volume":"109","author":"CL Licht","year":"2009","unstructured":"Licht CL, Marcussen AB, Wegener G, Overstreet DH, Aznar S, Knudsen GM. The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration. J Neurochem. 2009;109:1363\u201374.","journal-title":"J Neurochem"},{"key":"2107_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neuropharm.2016.08.037","volume":"111","author":"J Amig\u00f3","year":"2016","unstructured":"Amig\u00f3 J, D\u00edaz A, Pilar-Cu\u00e9llar F, Vidal R, Mart\u00edn A, Compan V, et al. The absence of 5-HT4 receptors modulates depression- and anxiety-like responses and influences the response of fluoxetine in olfactory bulbectomised mice: Adaptive changes in hippocampal neuroplasticity markers and 5-HT1A autoreceptor. Neuropharmacology. 2016;111:47\u201358.","journal-title":"Neuropharmacology"},{"key":"2107_CR24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.celrep.2017.10.003","volume":"21","author":"A Jean","year":"2017","unstructured":"Jean A, Laurent L, Delaunay S, Doly S, Dusticier N, Linden D, et al. Adaptive control of dorsal raphe by 5-HT4 in the prefrontal cortex prevents persistent hypophagia following stress. Cell Rep. 2017;21:901\u20139.","journal-title":"Cell Rep"},{"key":"2107_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.brainres.2012.04.019","volume":"1459","author":"A Chen","year":"2012","unstructured":"Chen A, Kelley LDS, Janu\u0161onis S. Effects of prenatal stress and monoaminergic perturbations on the expression of serotonin 5-HT4 and adrenergic \u03b22 receptors in the embryonic mouse telencephalon. Brain Res. 2012;1459:27\u201334.","journal-title":"Brain Res"},{"key":"2107_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.neuint.2010.01.003","volume":"56","author":"CL Licht","year":"2010","unstructured":"Licht CL, Kirkegaard L, Zueger M, Chourbaji S, Gass P, Aznar S, et al. Changes in 5-HT4 receptor and 5-HT transporter binding in olfactory bulbectomized and glucocorticoid receptor heterozygous mice. Neurochem Int. 2010;56:603\u201310.","journal-title":"Neurochem Int"},{"key":"2107_CR27","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.3390\/ijms19113581","volume":"19","author":"H Rebholz","year":"2018","unstructured":"Rebholz H, Friedman E, Castello J. Alterations of expression of the serotonin 5-HT4 receptor in brain disorders. Int J Mol Sci. 2018;19:3581.","journal-title":"Int J Mol Sci"},{"key":"2107_CR28","doi-asserted-by":"publisher","first-page":"pyu034","DOI":"10.1093\/ijnp\/pyu034","volume":"18","author":"K Madsen","year":"2014","unstructured":"Madsen K, Torstensen E, Holst KK, Haahr ME, Knorr U, Frokjaer VG, et al. Familial risk for major depression is associated with lower striatal 5-HT4 receptor binding. Int J Neuropsychopharmacol. 2014;18:pyu034.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2107_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamapsychiatry.2022.4539","volume":"80","author":"K K\u00f6hler-Forsberg","year":"2023","unstructured":"K\u00f6hler-Forsberg K, Dam VH, Ozenne B, Sankar A, Beliveau V, Landman EB, et al. Serotonin 4 receptor brain binding in major depressive disorder and association with memory dysfunction. JAMA Psychiatry. 2023;80:296\u2013304.","journal-title":"JAMA Psychiatry"},{"key":"2107_CR30","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.2174\/13816128113196660734","volume":"20","author":"R Vidal","year":"2014","unstructured":"Vidal R, Castro E, Pilar-Cu\u00e9llar F, Pascual-Brazo J, D\u00edaz A, Rojo ML, et al. Serotonin 5-HT4 receptors: A new strategy for developing fast acting antidepressants? Curr Pharm Des. 2014;20:3751\u201362.","journal-title":"Curr Pharm Des"},{"key":"2107_CR31","first-page":"1037","volume":"15","author":"A Kemp","year":"2005","unstructured":"Kemp A, Manahan-Vaughan D. The 5-hydroxytryptamine4 receptor exhibits frequency-dependent properties in synaptic plasticity and behavioural metaplasticity in the hippocampal CA1 region in vivo. Cereb Cortex N Y N 1991. 2005;15:1037\u201343.","journal-title":"Cereb Cortex N Y N 1991"},{"key":"2107_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/hipo.22569","volume":"26","author":"H Twarkowski","year":"2016","unstructured":"Twarkowski H, Hagena H, Manahan-Vaughan D. The 5-hydroxytryptamine4 receptor enables differentiation of informational content and encoding in the hippocampus. Hippocampus. 2016;26:875\u201391.","journal-title":"Hippocampus"},{"key":"2107_CR33","doi-asserted-by":"publisher","first-page":"e88085","DOI":"10.1371\/journal.pone.0088085","volume":"9","author":"M Wawra","year":"2014","unstructured":"Wawra M, Fidzinski P, Heinemann U, Mody I, Behr J. 5-HT4-receptors modulate induction of long-term depression but not potentiation at hippocampal output synapses in acute rat brain slices. PLoS ONE. 2014;9:e88085.","journal-title":"PLoS ONE"},{"key":"2107_CR34","doi-asserted-by":"publisher","first-page":"9683","DOI":"10.1523\/JNEUROSCI.1145-09.2009","volume":"29","author":"M-T Liu","year":"2009","unstructured":"Liu M-T, Kuan Y-H, Wang J, Hen R, Gershon MD. 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci. 2009;29:9683\u201399.","journal-title":"J Neurosci"},{"key":"2107_CR35","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/j.1476-5381.1996.tb15309.x","volume":"117","author":"J Ge","year":"1996","unstructured":"Ge J, Barnes NM. 5-HT4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. Br J Pharmacol. 1996;117:1475\u201380.","journal-title":"Br J Pharmacol"},{"key":"2107_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1017\/S1461145711000782","volume":"15","author":"J Pascual-Brazo","year":"2012","unstructured":"Pascual-Brazo J, Castro E, D\u00edaz A, Valdiz\u00e1n EM, Pilar-Cu\u00e9llar F, Vidal R, et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT4 receptor agonist RS67333. Int J Neuropsychopharmacol. 2012;15:631\u201343.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2107_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.neuron.2007.07.041","volume":"55","author":"G Lucas","year":"2007","unstructured":"Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron. 2007;55:712\u201325.","journal-title":"Neuron"},{"key":"2107_CR38","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41386-019-0540-3","volume":"45","author":"BK Chen","year":"2020","unstructured":"Chen BK, Mendez-David I, Luna VM, Faye C, Gardier AM, David DJ, et al. Prophylactic efficacy of 5-HT4R agonists against stress. Neuropsychopharmacology. 2020;45:542\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR39","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1017\/S0033291720000604","volume":"51","author":"SE Murphy","year":"2021","unstructured":"Murphy SE, de Cates AN, Gillespie AL, Godlewska BR, Scaife JC, Wright LC, et al. Translating the promise of 5HT4 receptor agonists for the treatment of depression. Psychol Med. 2021;51:1111\u201320.","journal-title":"Psychol Med"},{"key":"2107_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1124\/jpet.112.192351","volume":"341","author":"DE Johnson","year":"2012","unstructured":"Johnson DE, Drummond E, Grimwood S, Sawant-Basak A, Miller E, Tseng E, et al. The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal \u03b8 oscillations. J Pharmacol Exp Ther. 2012;341:681\u201391.","journal-title":"J Pharmacol Exp Ther"},{"key":"2107_CR41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/sj.bjp.0707178","volume":"150","author":"M Cachard-Chastel","year":"2007","unstructured":"Cachard-Chastel M, Lezoualc\u2019h F, Dewachter I, Delom\u00e9nie C, Croes S, Devijver H, et al. 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL\/6j mice. Br J Pharmacol. 2007;150:883\u201392.","journal-title":"Br J Pharmacol"},{"key":"2107_CR42","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1017\/S0033291719002836","volume":"50","author":"SE Murphy","year":"2020","unstructured":"Murphy SE, Wright LC, Browning M, Cowen PJ, Harmer CJ. A role for 5-HT4 receptors in human learning and memory. Psychol Med. 2020;50:2722\u201330.","journal-title":"Psychol Med"},{"key":"2107_CR43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.biopsych.2019.08.009","volume":"87","author":"C Faye","year":"2020","unstructured":"Faye C, Hen R, Guiard BP, Denny CA, Gardier AM, Mendez-David I, et al. Rapid anxiolytic effects of RS67333, a serotonin type 4 receptor agonist, and diazepam, a benzodiazepine, are mediated by projections from the prefrontal cortex to the dorsal raphe nucleus. Biol Psychiatry. 2020;87:514\u201325.","journal-title":"Biol Psychiatry"},{"key":"2107_CR44","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/npp.2013.332","volume":"39","author":"I Mendez-David","year":"2014","unstructured":"Mendez-David I, David DJ, Darcet F, Wu MV, Kerdine-R\u00f6mer S, Gardier AM, et al. Rapid anxiolytic effects of a 5-HT4 receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology. 2014;39:1366\u201378.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR45","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/j.1476-5381.1995.tb16628.x","volume":"115","author":"RM Eglen","year":"1995","unstructured":"Eglen RM, Bonhaus DW, Johnson LG, Leung E, Clark RD. Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br J Pharmacol. 1995;115:1387\u201392.","journal-title":"Br J Pharmacol"},{"key":"2107_CR46","doi-asserted-by":"publisher","first-page":"G768","DOI":"10.1152\/ajpgi.00036.2016","volume":"310","author":"F Bianco","year":"2016","unstructured":"Bianco F, Bonora E, Natarajan D, Vargiolu M, Thapar N, Torresan F, et al. Prucalopride exerts neuroprotection in human enteric neurons. Am J Physiol Gastrointest Liver Physiol. 2016;310:G768\u201375.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2107_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.neulet.2016.01.055","volume":"616","author":"F Darcet","year":"2016","unstructured":"Darcet F, Gardier AM, David DJ, Guilloux J-P. Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety\/depression. Neurosci Lett. 2016;616:197\u2013203.","journal-title":"Neurosci Lett"},{"key":"2107_CR48","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/acps.13211","volume":"142","author":"SV Larsen","year":"2020","unstructured":"Larsen SV, K\u00f6hler-Forsberg K, Dam VH, Poulsen AS, Svarer C, Jensen PS, et al. Oral contraceptives and the serotonin 4 receptor: a molecular brain imaging study in healthy women. Acta Psychiatr Scand. 2020;142:294\u2013306.","journal-title":"Acta Psychiatr Scand"},{"key":"2107_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02440-3","volume":"13","author":"A Sankar","year":"2023","unstructured":"Sankar A, Ozenne B, Dam VH, Svarer C, J\u00f8rgensen MB, Miskowiak KW, et al. Association between brain serotonin 4 receptor binding and reactivity to emotional faces in depressed and healthy individuals. Transl Psychiatry. 2023;13:165.","journal-title":"Transl Psychiatry"},{"key":"2107_CR50","doi-asserted-by":"crossref","unstructured":"Dam VH, K\u00f6hler-Forsberg K, Ozenne B, Larsen SV, Ip C-T, Jorgensen A, et al. Effect of antidepressant treatment on 5-HT4 receptor binding and associations with clinical outcomes and verbal memory in major depressive disorder. Biol Psychiatry. 2024:S0006-3223(24)01537-3.","DOI":"10.1016\/j.biopsych.2024.08.009"},{"key":"2107_CR51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.psyneuen.2016.01.032","volume":"67","author":"GR Jakobsen","year":"2016","unstructured":"Jakobsen GR, Fisher PM, Dyssegaard A, McMahon B, Holst KK, Lehel S, et al. Brain serotonin 4 receptor binding is associated with the cortisol awakening response. Psychoneuroendocrinology. 2016;67:124\u201332.","journal-title":"Psychoneuroendocrinology"},{"key":"2107_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.674","volume":"7","author":"DS Stenb\u00e6k","year":"2017","unstructured":"Stenb\u00e6k DS, Fisher PM, Ozenne B, Andersen E, Hjordt LV, McMahon B, et al. Brain serotonin 4 receptor binding is inversely associated with verbal memory recall. Brain Behav. 2017;7:e00674.","journal-title":"Brain Behav"},{"key":"2107_CR53","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1192\/bjp.2024.97","volume":"225","author":"AN de Cates","year":"2024","unstructured":"de Cates AN, Harmer CJ, Harrison PJ, Cowen PJ, Emmanuel A, Travis S, et al. Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial. Br J Psychiatry J Ment Sci. 2024;225:371\u20138.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"2107_CR54","doi-asserted-by":"crossref","unstructured":"Chen BK, Luna VM, Jin M, Shah A, Shannon ME, Pauers M, et al. A tale of two receptors: simultaneous targeting of NMDARs and 5-HT 4 Rs exerts additive effects against stress. bioRxiv. 2023:2023.09.27.559065.","DOI":"10.1101\/2023.09.27.559065"},{"key":"2107_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109357","volume":"225","author":"TML Nguyen","year":"2023","unstructured":"Nguyen TML, Defaix C, Mendez-David I, Tritschler L, Etting I, Alvarez J-C, et al. Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory\/inhibitory synaptic activity. Neuropharmacology. 2023;225:109357.","journal-title":"Neuropharmacology"},{"key":"2107_CR56","doi-asserted-by":"crossref","unstructured":"Hanson LR, Fine JM, Svitak AL, Faltesek KA. Intranasal administration of CNS therapeutics to awake mice. J Vis Exp. 2013;74:4440.","DOI":"10.3791\/4440-v"},{"key":"2107_CR57","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","volume":"173","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816\u201326.","journal-title":"Am J Psychiatry"},{"key":"2107_CR58","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/0269881114527361","volume":"28","author":"PR Diamond","year":"2014","unstructured":"Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol Oxf Engl. 2014;28:536\u201344.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"2107_CR59","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.3390\/ijms23115968","volume":"23","author":"M Bia\u0142o\u0144","year":"2022","unstructured":"Bia\u0142o\u0144 M, W\u0105sik A. Advantages and limitations of animal schizophrenia models. Int J Mol Sci. 2022;23:5968.","journal-title":"Int J Mol Sci"},{"key":"2107_CR60","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","volume":"45","author":"BK Chen","year":"2020","unstructured":"Chen BK, Luna VM, LaGamma CT, Xu X, Deng S-X, Suckow RF, et al. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. Neuropsychopharmacology. 2020;45:1545\u201356.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR61","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0165-1781(86)90075-2","volume":"17","author":"J Weissenburger","year":"1986","unstructured":"Weissenburger J, Rush AJ, Giles DE, Stunkard AJ. Weight change in depression. Psychiatry Res. 1986;17:275\u201383.","journal-title":"Psychiatry Res"},{"key":"2107_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12966-019-0791-8","volume":"16","author":"H Konttinen","year":"2019","unstructured":"Konttinen H, van Strien T, M\u00e4nnist\u00f6 S, Jousilahti P, Haukkala A. Depression, emotional eating and long-term weight changes: a population-based prospective study. Int J Behav Nutr Phys Act. 2019;16:28.","journal-title":"Int J Behav Nutr Phys Act"},{"key":"2107_CR63","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1176\/appi.ajp.2015.15020162","volume":"173","author":"WK Simmons","year":"2016","unstructured":"Simmons WK, Burrows K, Avery JA, Kerr KL, Bodurka J, Savage CR, et al. Depression-related increases and decreases in appetite: dissociable patterns of aberrant activity in reward and interoceptive neurocircuitry. Am J Psychiatry. 2016;173:418\u201328.","journal-title":"Am J Psychiatry"},{"key":"2107_CR64","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41380-018-0093-6","volume":"25","author":"WK Simmons","year":"2020","unstructured":"Simmons WK, Burrows K, Avery JA, Kerr KL, Taylor A, Bodurka J, et al. Appetite changes reveal depression subgroups with distinct endocrine, metabolic, and immune states. Mol Psychiatry. 2020;25:1457\u201368.","journal-title":"Mol Psychiatry"},{"key":"2107_CR65","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3390\/ijms25084511","volume":"25","author":"T Kukucka","year":"2024","unstructured":"Kukucka T, Ferencova N, Visnovcova Z, Ondrejka I, Hrtanek I, Kovacova V, et al. Mechanisms involved in the link between depression, antidepressant treatment, and associated weight change. Int J Mol Sci. 2024;25:4511.","journal-title":"Int J Mol Sci"},{"key":"2107_CR66","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/oby.22969","volume":"28","author":"H Gill","year":"2020","unstructured":"Gill H, Gill B, El-Halabi S, Chen-Li D, Lipsitz O, Rosenblat JD, et al. Antidepressant medications and weight change: a narrative review. Obes Silver Spring Md. 2020;28:2064\u201372.","journal-title":"Obes Silver Spring Md"},{"key":"2107_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1749-6632.1989.tb53229.x","volume":"575","author":"MH Fernstrom","year":"1989","unstructured":"Fernstrom MH. Depression, antidepressants, and body weight change. Ann N Y Acad Sci. 1989;575:31\u201339. discussion 39-40","journal-title":"Ann N Y Acad Sci"},{"key":"2107_CR68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"M Agrawal","year":"2018","unstructured":"Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, et al. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Controlled Release. 2018;281:139\u201377.","journal-title":"J Controlled Release"},{"key":"2107_CR69","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/pharmaceutics14102070","volume":"14","author":"Z Jin","year":"2022","unstructured":"Jin Z, Han Y, Zhang D, Li Z, Jing Y, Hu B, et al. Application of intranasal administration in the delivery of antidepressant active ingredients. Pharmaceutics. 2022;14:2070.","journal-title":"Pharmaceutics"},{"key":"2107_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"F Erd\u0151","year":"2018","unstructured":"Erd\u0151 F, Bors LA, Farkas D, Bajza \u00c1, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155\u201370.","journal-title":"Brain Res Bull"},{"key":"2107_CR71","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13346-021-00940-7","volume":"11","author":"LC Fonseca","year":"2021","unstructured":"Fonseca LC, Lopes JA, Vieira J, Viegas C, Oliveira CS, Hartmann RP, et al. Intranasal drug delivery for treatment of Alzheimer\u2019s disease. Drug Deliv Transl Res. 2021;11:411\u201325.","journal-title":"Drug Deliv Transl Res"},{"key":"2107_CR72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/17425247.2022.2029845","volume":"19","author":"P A","year":"2022","unstructured":"A P, Agrawal M, Dethe MR, Ahmed H, Yadav A, Gupta U, et al. Nose-to-brain drug delivery for the treatment of Alzheimer\u2019s disease: current advancements and challenges. Expert Opin Drug Deliv. 2022;19:87\u2013102.","journal-title":"Expert Opin Drug Deliv"},{"key":"2107_CR73","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neubiorev.2005.04.010","volume":"29","author":"V Rau","year":"2005","unstructured":"Rau V, DeCola JP, Fanselow MS. Stress-induced enhancement of fear learning: an animal model of posttraumatic stress disorder. Neurosci Biobehav Rev. 2005;29:1207\u201323.","journal-title":"Neurosci Biobehav Rev"},{"key":"2107_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104884","volume":"142","author":"KJ Nishimura","year":"2022","unstructured":"Nishimura KJ, Poulos AM, Drew MR, Rajbhandari AK. Know thy SEFL: Fear sensitization and its relevance to stressor-related disorders. Neurosci Biobehav Rev. 2022;142:104884.","journal-title":"Neurosci Biobehav Rev"},{"key":"2107_CR75","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fnbeh.2019.00104","volume":"13","author":"MA Conoscenti","year":"2019","unstructured":"Conoscenti MA, Fanselow MS. Dissociation in effective treatment and behavioral phenotype between stress-enhanced fear learning and learned helplessness. Front Behav Neurosci. 2019;13:104.","journal-title":"Front Behav Neurosci"},{"key":"2107_CR76","doi-asserted-by":"crossref","unstructured":"Rajbhandari AK, Gonzalez ST, Fanselow MS. Stress-enhanced fear learning, a robust rodent model of post-traumatic stress disorder. J Vis Exp. 2018;140:58306.","DOI":"10.3791\/58306-v"},{"key":"2107_CR77","first-page":"627","volume":"15","author":"VA Long","year":"2012","unstructured":"Long VA, Fanselow MS. Stress-enhanced fear learning in rats is resistant to the effects of immediate massed extinction. Stress Amst Neth. 2012;15:627\u201336.","journal-title":"Stress Amst Neth"},{"key":"2107_CR78","first-page":"125","volume":"12","author":"V Rau","year":"2009","unstructured":"Rau V, Fanselow MS. Exposure to a stressor produces a long lasting enhancement of fear learning in rats. Stress Amst Neth. 2009;12:125\u201333.","journal-title":"Stress Amst Neth"},{"key":"2107_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/npp.2015.224","volume":"41","author":"JN Perusini","year":"2016","unstructured":"Perusini JN, Meyer EM, Long VA, Rau V, Nocera N, Avershal J, et al. Induction and expression of fear sensitization caused by acute traumatic stress. Neuropsychopharmacology. 2016;41:45\u201357.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112391","volume":"379","author":"AM Hassien","year":"2020","unstructured":"Hassien AM, Shue F, Bernier BE, Drew MR. A mouse model of stress-enhanced fear learning demonstrates extinction-sensitive and extinction-resistant effects of footshock stress. Behav Brain Res. 2020;379:112391.","journal-title":"Behav Brain Res"},{"key":"2107_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30386-5","volume":"13","author":"R Rawat","year":"2022","unstructured":"Rawat R, Tunc-Ozcan E, McGuire TL, Peng C-Y, Kessler JA. Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice. Nat Commun. 2022;13:2650.","journal-title":"Nat Commun"},{"key":"2107_CR82","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.1083328","volume":"301","author":"L Santarelli","year":"2003","unstructured":"Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805\u20139.","journal-title":"Science"},{"key":"2107_CR83","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.neuron.2009.04.017","volume":"62","author":"DJ David","year":"2009","unstructured":"David DJ, Samuels BA, Rainer Q, Wang J-W, Marsteller D, Mendez I, et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety\/depression. Neuron. 2009;62:479\u201393.","journal-title":"Neuron"},{"key":"2107_CR84","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/npp.2015.85","volume":"40","author":"AS Hill","year":"2015","unstructured":"Hill AS, Sahay A, Hen R. Increasing adult hippocampal neurogenesis is sufficient to reduce anxiety and depression-like behaviors. Neuropsychopharmacology. 2015;40:2368\u201378.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR85","first-page":"196","volume":"29","author":"JE Malberg","year":"2004","unstructured":"Malberg JE. Implications of adult hippocampal neurogenesis in antidepressant action. J Psychiatry Neurosci. 2004;29:196\u2013205.","journal-title":"J Psychiatry Neurosci"},{"key":"2107_CR86","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1038\/npp.2011.220","volume":"36","author":"ND Hanson","year":"2011","unstructured":"Hanson ND, Owens MJ, Nemeroff CB. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology. 2011;36:2589\u2013602.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR87","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.3390\/ijms23094999","volume":"23","author":"OV Dolotov","year":"2022","unstructured":"Dolotov OV, Inozemtseva LS, Myasoedov NF, Grivennikov IA. Stress-induced depression and Alzheimer\u2019s disease: focus on astrocytes. Int J Mol Sci. 2022;23:4999.","journal-title":"Int J Mol Sci"},{"key":"2107_CR88","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2174\/187152707780619326","volume":"6","author":"G Rajkowska","year":"2007","unstructured":"Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6:219\u201333.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2107_CR89","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/nn1340","volume":"7","author":"ADR Garcia","year":"2004","unstructured":"Garcia ADR, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci. 2004;7:1233\u201341.","journal-title":"Nat Neurosci"},{"key":"2107_CR90","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0896-6273(04)00140-0","volume":"41","author":"TE Anthony","year":"2004","unstructured":"Anthony TE, Klein C, Fishell G, Heintz N. Radial glia serve as neuronal progenitors in all regions of the central nervous system. Neuron. 2004;41:881\u201390.","journal-title":"Neuron"},{"key":"2107_CR91","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0896-6273(03)00116-8","volume":"37","author":"P Malatesta","year":"2003","unstructured":"Malatesta P, Hack MA, Hartfuss E, Kettenmann H, Klinkert W, Kirchhoff F, et al. Neuronal or glial progeny: regional differences in radial glia fate. Neuron. 2003;37:751\u201364.","journal-title":"Neuron"},{"key":"2107_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00441-011-1196-4","volume":"345","author":"O von Bohlen und Halbach","year":"2011","unstructured":"von Bohlen und Halbach O. Immunohistological markers for proliferative events, gliogenesis, and neurogenesis within the adult hippocampus. Cell Tissue Res. 2011;345:1\u201319.","journal-title":"Cell Tissue Res"},{"key":"2107_CR93","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0165-0270(02)00007-9","volume":"115","author":"N Kee","year":"2002","unstructured":"Kee N, Sivalingam S, Boonstra R, Wojtowicz JM. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J Neurosci Methods. 2002;115:97\u2013105.","journal-title":"J Neurosci Methods"},{"key":"2107_CR94","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311\u201322.","journal-title":"J Cell Physiol"},{"key":"2107_CR95","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00441-013-1654-2","volume":"354","author":"B Vollmayr","year":"2013","unstructured":"Vollmayr B, Gass P. Learned helplessness: unique features and translational value of a cognitive depression model. Cell Tissue Res. 2013;354:171\u20138.","journal-title":"Cell Tissue Res"},{"key":"2107_CR96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.brainresprot.2005.09.002","volume":"16","author":"S Chourbaji","year":"2005","unstructured":"Chourbaji S, Zacher C, Sanchis-Segura C, Dormann C, Vollmayr B, Gass P. Learned helplessness: validity and reliability of depressive-like states in mice. Brain Res Brain Res Protoc. 2005;16:70\u201378.","journal-title":"Brain Res Brain Res Protoc"},{"key":"2107_CR97","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.nbd.2006.05.001","volume":"23","author":"S Chourbaji","year":"2006","unstructured":"Chourbaji S, Urani A, Inta I, Sanchis-Segura C, Brandwein C, Zink M, et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol Dis. 2006;23:587\u201394.","journal-title":"Neurobiol Dis"},{"key":"2107_CR98","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1176\/appi.ajp.157.2.229","volume":"157","author":"DA Solomon","year":"2000","unstructured":"Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157:229\u201333.","journal-title":"Am J Psychiatry"},{"key":"2107_CR99","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2005.07.008","volume":"40","author":"SD Hollon","year":"2006","unstructured":"Hollon SD, Shelton RC, Wisniewski S, Warden D, Biggs MM, Friedman ES, et al. Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. J Psychiatr Res. 2006;40:59\u201369.","journal-title":"J Psychiatr Res"},{"key":"2107_CR100","doi-asserted-by":"publisher","first-page":"113070","DOI":"10.1016\/j.physbeh.2020.113070","volume":"224","author":"KA Lebedeva","year":"2020","unstructured":"Lebedeva KA, Allen J, Kulhawy EY, Caruncho HJ, Kalynchuk LE. Cyclical administration of corticosterone results in aggravation of depression-like behaviors and accompanying downregulations in reelin in an animal model of chronic stress relevant to human recurrent depression. Physiol Behav. 2020;224:113070.","journal-title":"Physiol Behav"},{"key":"2107_CR101","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1037\/pha0000112","volume":"25","author":"M Mekiri","year":"2017","unstructured":"Mekiri M, Gardier AM, David DJ, Guilloux J-P. Chronic corticosterone administration effects on behavioral emotionality in female c57bl6 mice. Exp Clin Psychopharmacol. 2017;25:94\u2013104.","journal-title":"Exp Clin Psychopharmacol"},{"key":"2107_CR102","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/j.2051-5545.2011.tb00061.x","volume":"10","author":"D Goldberg","year":"2011","unstructured":"Goldberg D. The heterogeneity of \u2018major depression. World Psychiatry. 2011;10:226\u20138.","journal-title":"World Psychiatry"},{"key":"2107_CR103","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11033-019-05129-3","volume":"47","author":"E Pitsillou","year":"2020","unstructured":"Pitsillou E, Bresnehan SM, Kagarakis EA, Wijoyo SJ, Liang J, Hung A, et al. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. Mol Biol Rep. 2020;47:753\u201370.","journal-title":"Mol Biol Rep"},{"key":"2107_CR104","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","volume":"302","author":"NA Nu\u00f1ez","year":"2022","unstructured":"Nu\u00f1ez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord. 2022;302:385\u2013400.","journal-title":"J Affect Disord"},{"key":"2107_CR105","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22:616\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2107_CR106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:139\u201348.","journal-title":"JAMA Psychiatry"},{"key":"2107_CR107","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","volume":"28","author":"R Ochs-Ross","year":"2020","unstructured":"Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020;28:121\u201341.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2107_CR108","doi-asserted-by":"publisher","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","volume":"81","author":"E Wajs","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry. 2020;81:19m12891.","journal-title":"J Clin Psychiatry"},{"key":"2107_CR109","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","volume":"48","author":"N Zaki","year":"2023","unstructured":"Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 2023;48:1225\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR110","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/02698811221104058","volume":"37","author":"F Scott","year":"2023","unstructured":"Scott F, Hampsey E, Gnanapragasam S, Carter B, Marwood L, Taylor RW, et al. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. J Psychopharmacol Oxf Engl. 2023;37:268\u201378.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"2107_CR111","first-page":"937","volume":"4","author":"JC Nelson","year":"2008","unstructured":"Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat. 2008;4:937\u201348.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2107_CR112","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamapsychiatry.2021.4313","volume":"79","author":"J Henssler","year":"2022","unstructured":"Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C. Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression: a systematic review and meta-analysis. JAMA Psychiatry. 2022;79:300\u201312.","journal-title":"JAMA Psychiatry"},{"key":"2107_CR113","doi-asserted-by":"publisher","first-page":"191","DOI":"10.31887\/DCNS.2005.7.3\/dkupfer","volume":"7","author":"DJ Kupfer","year":"2005","unstructured":"Kupfer DJ. The pharmacological management of depression. Dialogues Clin Neurosci. 2005;7:191\u2013205.","journal-title":"Dialogues Clin Neurosci"},{"key":"2107_CR114","doi-asserted-by":"publisher","first-page":"e0230363","DOI":"10.1371\/journal.pone.0230363","volume":"15","author":"M-S Lye","year":"2020","unstructured":"Lye M-S, Tey Y-Y, Tor Y-S, Shahabudin AF, Ibrahim N, Ling K-H, et al. Predictors of recurrence of major depressive disorder. PLoS ONE. 2020;15:e0230363.","journal-title":"PLoS ONE"},{"key":"2107_CR115","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1037\/a0025190","volume":"118","author":"SM Monroe","year":"2011","unstructured":"Monroe SM, Harkness KL. Recurrence in major depression: a conceptual analysis. Psychol Rev. 2011;118:655\u201374.","journal-title":"Psychol Rev"},{"key":"2107_CR116","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm"},{"key":"2107_CR117","unstructured":"Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 2005."},{"key":"2107_CR118","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.4088\/JCP.17f11738","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78:e852\u20137.","journal-title":"J Clin Psychiatry"},{"key":"2107_CR119","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","volume":"42","author":"T-P Su","year":"2017","unstructured":"Su T-P, Chen M-H, Li C-T, Lin W-C, Hong C-J, Gueorguieva R, et al. Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42:2482\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR120","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","volume":"47","author":"CG Abdallah","year":"2022","unstructured":"Abdallah CG, Roache JD, Gueorguieva R, Averill LA, Young-McCaughan S, Shiroma PR, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47:1574\u201381.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR121","doi-asserted-by":"crossref","unstructured":"Derakhchan K, Lou Z, Wang H, Baughman R. Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies. Drugs Context. 2023;12:2022-6\u20131.","DOI":"10.7573\/dic.2022-6-1"},{"key":"2107_CR122","first-page":"e14306","volume":"13","author":"H Ali","year":"2021","unstructured":"Ali H, Pamarthy R, Sarfraz S. Role of prucalopride in treating functional constipation and gastroparesis: a systemic review. Cureus. 2021;13:e14306.","journal-title":"Cureus"},{"key":"2107_CR123","doi-asserted-by":"publisher","first-page":"955","DOI":"10.14309\/ajg.0000000000002249","volume":"118","author":"J Tack","year":"2023","unstructured":"Tack J, Derakhchan K, Gabriel A, Spalding W, Terreri B, Youssef A, et al. A review of the cardiovascular safety of prucalopride in patients with chronic idiopathic constipation. Am J Gastroenterol. 2023;118:955\u201360.","journal-title":"Am J Gastroenterol"},{"key":"2107_CR124","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"L-A Keller","year":"2022","unstructured":"Keller L-A, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;12:735\u201357.","journal-title":"Drug Deliv Transl Res"},{"key":"2107_CR125","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1091581817741840","volume":"37","author":"A Emami","year":"2018","unstructured":"Emami A, Tepper J, Short B, Yaksh TL, Bendele AM, Ramani T, et al. Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal\/Intraspinal, and Intra-Articular. Int J Toxicol. 2018;37:4\u201327.","journal-title":"Int J Toxicol"},{"key":"2107_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2022.100581","volume":"21","author":"S Chung","year":"2023","unstructured":"Chung S, Peters JM, Detyniecki K, Tatum W, Rabinowicz AL, Carrazana E. The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters. Epilepsy Behav Rep. 2023;21:100581.","journal-title":"Epilepsy Behav Rep"},{"key":"2107_CR127","first-page":"105","volume":"2","author":"S Gizurarson","year":"1990","unstructured":"Gizurarson S. Animal models for intranasal drug delivery studies. A review article. Acta Pharm Nord. 1990;2:105\u201322.","journal-title":"Acta Pharm Nord"},{"key":"2107_CR128","doi-asserted-by":"crossref","unstructured":"Demetrius L. Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans. EMBO Rep. 2005;6:S39-44.","DOI":"10.1038\/sj.embor.7400422"},{"key":"2107_CR129","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/jn\/131.7.2067","volume":"131","author":"AH Terpstra","year":"2001","unstructured":"Terpstra AH. Differences between humans and mice in efficacy of the body fat lowering effect of conjugated linoleic acid: role of metabolic rate. J Nutr. 2001;131:2067\u20138.","journal-title":"J Nutr"},{"key":"2107_CR130","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0736-5748(98)00029-X","volume":"16","author":"P Tanapat","year":"1998","unstructured":"Tanapat P, Galea LA, Gould E. Stress inhibits the proliferation of granule cell precursors in the developing dentate gyrus. Int J Dev Neurosci. 1998;16:235\u20139.","journal-title":"Int J Dev Neurosci"},{"key":"2107_CR131","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cne.1297","volume":"437","author":"P Tanapat","year":"2001","unstructured":"Tanapat P, Hastings NB, Rydel TA, Galea LA, Gould E. Exposure to fox odor inhibits cell proliferation in the hippocampus of adult rats via an adrenal hormone-dependent mechanism. J Comp Neurol. 2001;437:496\u2013504.","journal-title":"J Comp Neurol"},{"key":"2107_CR132","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/sj.npp.1300234","volume":"28","author":"JE Malberg","year":"2003","unstructured":"Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003;28:1562\u201371.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR133","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1046\/j.1460-9568.2003.02513.x","volume":"17","author":"K Pham","year":"2003","unstructured":"Pham K, Nacher J, Hof PR, McEwen BS. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. Eur J Neurosci. 2003;17:879\u201386.","journal-title":"Eur J Neurosci"},{"key":"2107_CR134","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1523\/JNEUROSCI.17-07-02492.1997","volume":"17","author":"E Gould","year":"1997","unstructured":"Gould E, McEwen BS, Tanapat P, Galea LA, Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J Neurosci. 1997;17:2492\u20138.","journal-title":"J Neurosci"},{"key":"2107_CR135","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1176\/ajp.157.1.115","volume":"157","author":"JD Bremner","year":"2000","unstructured":"Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157:115\u20138.","journal-title":"Am J Psychiatry"},{"key":"2107_CR136","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1073\/pnas.93.9.3908","volume":"93","author":"YI Sheline","year":"1996","unstructured":"Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA. 1996;93:3908\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2107_CR137","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1176\/appi.ajp.160.8.1516","volume":"160","author":"YI Sheline","year":"2003","unstructured":"Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516\u20138.","journal-title":"Am J Psychiatry"},{"key":"2107_CR138","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1523\/JNEUROSCI.19-12-05034.1999","volume":"19","author":"YI Sheline","year":"1999","unstructured":"Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999;19:5034\u201343.","journal-title":"J Neurosci"},{"key":"2107_CR139","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1073\/pnas.0337481100","volume":"100","author":"GM MacQueen","year":"2003","unstructured":"MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA. 2003;100:1387\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2107_CR140","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1038\/s41380-022-01520-y","volume":"27","author":"AN Tartt","year":"2022","unstructured":"Tartt AN, Mariani MB, Hen R, Mann JJ, Boldrini M. Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications. Mol Psychiatry. 2022;27:2689\u201399.","journal-title":"Mol Psychiatry"},{"key":"2107_CR141","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.2174\/1570159X18666200818194948","volume":"19","author":"M Carli","year":"2021","unstructured":"Carli M, Aringhieri S, Kolachalam S, Longoni B, Grenno G, Rossi M, et al. Is adult hippocampal neurogenesis really relevant for the treatment of psychiatric disorders? Curr Neuropharmacol. 2021;19:1640\u201360.","journal-title":"Curr Neuropharmacol"},{"key":"2107_CR142","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.coph.2019.11.009","volume":"50","author":"B Planchez","year":"2020","unstructured":"Planchez B, Surget A, Belzung C. Adult hippocampal neurogenesis and antidepressants effects. Curr Opin Pharmacol. 2020;50:88\u201395.","journal-title":"Curr Opin Pharmacol"},{"key":"2107_CR143","doi-asserted-by":"publisher","first-page":"172837","DOI":"10.1016\/j.pbb.2019.172837","volume":"188","author":"S Deyama","year":"2020","unstructured":"Deyama S, Duman RS. Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. Pharmacol Biochem Behav. 2020;188:172837.","journal-title":"Pharmacol Biochem Behav"},{"key":"2107_CR144","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.neubiorev.2013.11.009","volume":"38","author":"I Mahar","year":"2014","unstructured":"Mahar I, Bambico FR, Mechawar N, Nobrega JN. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci Biobehav Rev. 2014;38:173\u201392.","journal-title":"Neurosci Biobehav Rev"},{"key":"2107_CR145","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharma.2013.02.006","volume":"71","author":"I Mendez-David","year":"2013","unstructured":"Mendez-David I, Hen R, Gardier AM, David DJ. Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann Pharm Fr. 2013;71:143\u20139.","journal-title":"Ann Pharm Fr"},{"key":"2107_CR146","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/FBP.0b013e3282ee2aa8","volume":"18","author":"HD Schmidt","year":"2007","unstructured":"Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007;18:391\u2013418.","journal-title":"Behav Pharmacol"},{"key":"2107_CR147","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.2174\/092986711797200471","volume":"18","author":"H-C Yan","year":"2011","unstructured":"Yan H-C, Cao X, Gao T-M, Zhu X-H. Promoting adult hippocampal neurogenesis: a novel strategy for antidepressant drug screening. Curr Med Chem. 2011;18:4359\u201367.","journal-title":"Curr Med Chem"},{"key":"2107_CR148","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/nn1969","volume":"10","author":"A Sahay","year":"2007","unstructured":"Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007;10:1110\u20135.","journal-title":"Nat Neurosci"},{"key":"2107_CR149","doi-asserted-by":"publisher","first-page":"73754","DOI":"10.1155\/2007\/73754","volume":"2007","author":"E Paizanis","year":"2007","unstructured":"Paizanis E, Hamon M, Lanfumey L. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast. 2007;2007:73754.","journal-title":"Neural Plast"},{"key":"2107_CR150","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2174\/187152707780619353","volume":"6","author":"MR Drew","year":"2007","unstructured":"Drew MR, Hen R. Adult hippocampal neurogenesis as target for the treatment of depression. CNS Neurol Disord Drug Targets. 2007;6:205\u201318.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2107_CR151","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1586\/14737175.7.7.853","volume":"7","author":"VA Vaidya","year":"2007","unstructured":"Vaidya VA, Fernandes K, Jha S. Regulation of adult hippocampal neurogenesis: relevance to depression. Expert Rev Neurother. 2007;7:853\u201364.","journal-title":"Expert Rev Neurother"},{"key":"2107_CR152","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.biopsych.2006.03.082","volume":"59","author":"A Dranovsky","year":"2006","unstructured":"Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry. 2006;59:1136\u201343.","journal-title":"Biol Psychiatry"},{"key":"2107_CR153","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/hipo.20156","volume":"16","author":"JL Warner-Schmidt","year":"2006","unstructured":"Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus. 2006;16:239\u201349.","journal-title":"Hippocampus"},{"key":"2107_CR154","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1381612053382223","volume":"11","author":"JE Malberg","year":"2005","unstructured":"Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des. 2005;11:145\u201355.","journal-title":"Curr Pharm Des"},{"key":"2107_CR155","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.biopsych.2021.01.010","volume":"90","author":"JE Malberg","year":"2021","unstructured":"Malberg JE, Hen R, Madsen TM. Adult neurogenesis and antidepressant treatment: the surprise finding by ron duman and the Field 20 Years Later. Biol Psychiatry. 2021;90:96\u2013101.","journal-title":"Biol Psychiatry"},{"key":"2107_CR156","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bcp.2017.08.005","volume":"141","author":"H Eliwa","year":"2017","unstructured":"Eliwa H, Belzung C, Surget A. Adult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action? Biochem Pharmacol. 2017;141:86\u201399.","journal-title":"Biochem Pharmacol"},{"key":"2107_CR157","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat8078","volume":"364","author":"RN Moda-Sava","year":"2019","unstructured":"Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat8078.","journal-title":"Science"},{"key":"2107_CR158","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.nicl.2018.07.006","volume":"20","author":"JL Reed","year":"2018","unstructured":"Reed JL, Nugent AC, Furey ML, Szczepanik JE, Evans JW, Zarate CA. Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. NeuroImage Clin. 2018;20:92\u2013101.","journal-title":"NeuroImage Clin"},{"key":"2107_CR159","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.biopsych.2018.01.027","volume":"84","author":"JW Evans","year":"2018","unstructured":"Evans JW, Szczepanik J, Brutsch\u00e9 N, Park LT, Nugent AC, Zarate CA. Default mode connectivity in major depressive disorder measured Up to 10 days after ketamine administration. Biol Psychiatry. 2018;84:582\u201390.","journal-title":"Biol Psychiatry"},{"key":"2107_CR160","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/sj.npp.1301644","volume":"33","author":"L Restivo","year":"2008","unstructured":"Restivo L, Roman F, Dumuis A, Bockaert J, Marchetti E, Ammassari-Teule M. The promnesic effect of G-protein-coupled 5-HT4 receptors activation is mediated by a potentiation of learning-induced spine growth in the mouse hippocampus. Neuropsychopharmacology. 2008;33:2427\u201334.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01568-4","volume":"11","author":"AN de Cates","year":"2021","unstructured":"de Cates AN, Wright LC, Martens MAG, Gibson D, T\u00fcrkmen C, Filippini N, et al. D\u00e9j\u00e0-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task. Transl Psychiatry. 2021;11:497.","journal-title":"Transl Psychiatry"},{"key":"2107_CR162","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41380-024-02625-2","volume":"29","author":"CE Page","year":"2024","unstructured":"Page CE, Epperson CN, Novick AM, Duffy KA, Thompson SM. Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder. Mol Psychiatry. 2024;29:3802\u201313.","journal-title":"Mol Psychiatry"},{"key":"2107_CR163","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2174\/1389450110607011399","volume":"7","author":"TD Gould","year":"2006","unstructured":"Gould TD, Picchini AM, Einat H, Manji HK. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets. 2006;7:1399\u2013409.","journal-title":"Curr Drug Targets"},{"key":"2107_CR164","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.3390\/ijms23084413","volume":"23","author":"M Marosi","year":"2022","unstructured":"Marosi M, Arman P, Aceto G, D\u2019Ascenzo M, Laezza F. Glycogen synthase kinase 3: ion channels, plasticity, and diseases. Int J Mol Sci. 2022;23:4413.","journal-title":"Int J Mol Sci"},{"key":"2107_CR165","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/mp.2011.47","volume":"16","author":"E Beurel","year":"2011","unstructured":"Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. 2011;16:1068\u201370.","journal-title":"Mol Psychiatry"},{"key":"2107_CR166","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/npp.2013.128","volume":"38","author":"R-J Liu","year":"2013","unstructured":"Liu R-J, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology. 2013;38:2268\u201377.","journal-title":"Neuropsychopharmacology"},{"key":"2107_CR167","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1523\/JNEUROSCI.5343-08.2009","volume":"29","author":"JL Warner-Schmidt","year":"2009","unstructured":"Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, Svenningsson P, et al. Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci. 2009;29:1937\u201346.","journal-title":"J Neurosci"},{"key":"2107_CR168","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0026-895X(25)08518-9","volume":"47","author":"GE Torres","year":"1995","unstructured":"Torres GE, Chaput Y, Andrade R. Cyclic AMP and protein kinase A mediate 5-hydroxytryptamine type 4 receptor regulation of calcium-activated potassium current in adult hippocampal neurons. Mol Pharmacol. 1995;47:191\u20137.","journal-title":"Mol Pharmacol"},{"key":"2107_CR169","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1113\/jphysiol.2001.013391","volume":"540","author":"X Cai","year":"2002","unstructured":"Cai X, Flores-Hernandez J, Feng J, Yan Z. Activity-dependent bidirectional regulation of GABA(A) receptor channels by the 5-HT(4) receptor-mediated signalling in rat prefrontal cortical pyramidal neurons. J Physiol. 2002;540:743\u201359.","journal-title":"J Physiol"},{"key":"2107_CR170","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1101\/lm.593407","volume":"14","author":"Y-Y Huang","year":"2007","unstructured":"Huang Y-Y, Kandel ER. Low-frequency stimulation induces a pathway-specific late phase of LTP in the amygdala that is mediated by PKA and dependent on protein synthesis. Learn Mem Cold Spring Harb N. 2007;14:497\u2013503.","journal-title":"Learn Mem Cold Spring Harb N"},{"key":"2107_CR171","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1091\/mbc.e06-12-1080","volume":"18","author":"G Barthet","year":"2007","unstructured":"Barthet G, Framery B, Gaven F, Pellissier L, Reiter E, Claeysen S, et al. 5-hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling. Mol Biol Cell. 2007;18:1979\u201391.","journal-title":"Mol Biol Cell"},{"key":"2107_CR172","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.brainres.2016.11.021","volume":"1655","author":"N Kozono","year":"2017","unstructured":"Kozono N, Ohtani A, Shiga T. Roles of the serotonin 5-HT4 receptor in dendrite formation of the rat hippocampal neurons in vitro. Brain Res. 2017;1655:114\u201321.","journal-title":"Brain Res"},{"key":"2107_CR173","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/cells9030727","volume":"9","author":"P Duda","year":"2020","unstructured":"Duda P, Hajka D, W\u00f3jcicka O, Rakus D, Gizak A. GSK3\u03b2: A master player in depressive disorder pathogenesis and treatment responsiveness. Cells. 2020;9:727.","journal-title":"Cells"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02107-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02107-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02107-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T13:02:44Z","timestamp":1750078964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02107-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":173,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2107"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02107-1","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BKC, CAD, IM-D, DJD, and AMG are named on provisional and non-provisional patent applications for the prophylactic use of (R,S)-ketamine, 5-HT4R agonists, and other compounds against stress-related psychiatric disorders and Alzheimer\u2019s disease. BKC is currently Special Projects Manager at NPP. SJ is employed by Silo Pharma, and EW is founder and Chief Executive Officer of Silo Pharma. AW, LCM, and TM have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}